Condition
Flaviviridae Infections
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
66.7%
2 terminated out of 3 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results33% success
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 4 (1)
Trial Status
Terminated2
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02613403Phase 2Terminated
Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
NCT03110770Phase 2Completed
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
NCT02120274Phase 4Terminated
Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C
Showing all 3 trials